Curis Inc. of Lexington received positive data from a pivotal Phase 2 trial  of its GDC-0449 drug candidate for advanced basal cell carcinoma (BCC), a disfiguring and debilitating skin cancer, that will allow its partner Genentech to file for a new drug application (NDA) in the second half of this year, triggering a milestone payment for Curis.
“The response rate in this trial is significant enough to be compelling. This is a pivotal Phase 2 trial,” said Daniel Passeri, president and CEO of Curis. “There is no alternative for this patient population. They have tried other therapies, but they weren’t effective.” The data will be presented on June 21 at the Seventh European Association of Dermato-Oncology Congress in Nantes, France.